Vicore Pharma Holding AB (OSTO:VICO) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Apr. 17, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Vicore Pharma Holding AB Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Vicore Pharma Holding AB's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Vicore Pharma Holding AB's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Vicore Pharma Holding AB's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Vicore Pharma Holding AB (OSTO:VICO) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Vicore Pharma Holding AB Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

6Y4:Germany

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines